<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04849481</url>
  </required_header>
  <id_info>
    <org_study_id>T1521</org_study_id>
    <nct_id>NCT04849481</nct_id>
  </id_info>
  <brief_title>The Research Plan of Taiwan Precision Medicine</brief_title>
  <official_title>The Research Plan of Taiwan Precision Medicine: Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Health Research Institutes, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Health Research Institutes, Taiwan</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-small-cell lung cancer (NSCLC) is one of the top three most common cancers in Taiwan.&#xD;
      Targetable driver mutations in NSCLC are more prevalent in Asian population compared to those&#xD;
      in Western population, which offers chances to apply suitable targeted therapies worldwide.&#xD;
      For patients who failed to the treatment of tyrosine kinase inhibitors (TKIs), the genetic&#xD;
      mutations from next-generation sequencing (NGS) reports can serve as the reference of&#xD;
      treatment selection. Moreover, the expression of PD-1/PD-L1 serves as a helpful indicator for&#xD;
      the response of immune checkpoint inhibitors (ICIs). On the other hand, patients with&#xD;
      wild-type EGFR/ALK mutations and PD-L1-negative NSCLC who received chemotherapy had relative&#xD;
      poorer survival than those received suitable targeted therapies and ICIs. To further&#xD;
      elucidate the underlying molecular genomic aberrations, as well as the clinical demographics&#xD;
      and therapeutic outcomes in above subpopulations, it is necessary to have a national,&#xD;
      multi-centers and population-focused research project to collect data completely. Tumor&#xD;
      tissue will be collected from advanced NSCLC patients with wild-type EGFR/ALK or EGFR/ALK&#xD;
      mutation after resistant to TKIs for real-time next-generation sequencing analysis in a&#xD;
      platform of data storage and sharing. The purpose of the precision medicine project is to&#xD;
      establish tumor molecular profiling of specific NSCLC populations in Taiwan, to facilitate&#xD;
      patients to have corresponding potential targeted therapeutics and suitable clinical trials,&#xD;
      and to extend the median overall survival.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Development of an integrated database of genetic background from treatment-naïve and&#xD;
      TKI-refractory populations, clinical information, and therapeutic outcomes in advanced NSCLC.&#xD;
&#xD;
        1. To enroll 500 patients who fit the criteria of this study in the enrolled period.&#xD;
&#xD;
        2. To perform large-scale NGS analysis for specific populations, create a map containing&#xD;
           important genetic characteristics to help understand the mechanisms of drug resistance,&#xD;
           and find novel treatment strategies.&#xD;
&#xD;
        3. To collect tumor sample collection for NGS testing&#xD;
&#xD;
        4. To record previous therapeutic agents and accompanying treatment response and adverse&#xD;
           events&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 30, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2028</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To perform large-scale NGS analysis for specific populations, create a map containing important genetic characteristics to help understand the mechanisms of drug resistance, and find novel treatment strategies.</measure>
    <time_frame>2021/05~2028/12</time_frame>
    <description>Development of an integrated database of genetic background from treatment-naïve and TKI-refractory populations, clinical information, and therapeutic outcomes in advanced NSCLC.</description>
  </primary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Non-small-cell Lung Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Next-generation sequencing&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        1. For patients with advanced EGFR/ALK (-) tumors, treatment-naïve or failure to ≤ two&#xD;
             lines of systemic treatment.&#xD;
&#xD;
          2. For patients with advanced EGFR/ALK (+) tumors, failure to ≤ two lines of systemic&#xD;
             treatment, such as tyrosine kinase inhibitors.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  Inclusion Criteria&#xD;
&#xD;
               1. Ages 20 and above.&#xD;
&#xD;
               2. Pathological reported showed adenocarcinoma、squamous cell carcinoma、large cell&#xD;
                  carcinoma、adenosquamous carcinoma, and sacromatoid carcinoma.&#xD;
&#xD;
               3. For patients with squamous cell carcinoma, only never smokers and light smokers&#xD;
                  (less than 10 cigarettes per day) are indicated.&#xD;
&#xD;
               4. For patients with advanced EGFR/ALK (-) tumors, treatment-naïve or failure to ≤&#xD;
                  two lines of systemic treatment.&#xD;
&#xD;
               5. For patients with advanced EGFR/ALK (+) tumors, failure to ≤ two lines of&#xD;
                  systemic treatment, such as tyrosine kinase inhibitors.&#xD;
&#xD;
               6. Reacquisition of tumor tissue after the failure of previous systemic treatment&#xD;
&#xD;
               7. Willingness to provide the residual biopsy/operative slides.&#xD;
&#xD;
               8. Life expectancy more than 3 months.&#xD;
&#xD;
               9. Patients fully understand the protocol with the willingness to have regular&#xD;
                  follow-up.&#xD;
&#xD;
          -  Exclusion Criteria&#xD;
&#xD;
               1. Inability to cooperate by providing a complete medical history.&#xD;
&#xD;
               2. No available tumor tissues for genetic testing.&#xD;
&#xD;
               3. Undesirable compliance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nai-Jung Chiang</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Health Research Institutes, Taiwan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ya-Ling Wu</last_name>
    <phone>886-3-7206166</phone>
    <phone_ext>35119</phone_ext>
    <email>yalin@nhri.edu.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nai-Jung Chiang</last_name>
    <phone>886-6-7000123</phone>
    <phone_ext>65148</phone_ext>
    <email>njchiang@nhri.org.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dalin Tzu Chi Hospital</name>
      <address>
        <city>Dalin</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <contact>
      <last_name>Chun-Liang Lai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <contact>
      <last_name>Chong, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <contact>
      <last_name>Te-Chun Hsia, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chung Shan Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <contact>
      <last_name>Gee-Chen Chang, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <contact>
      <last_name>Tsung-Ying Yang, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <contact>
      <last_name>Wu-Chou Su, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <contact>
      <last_name>Chih-Hsin Yang, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <contact>
      <last_name>Yung-Hung Luo, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 15, 2021</study_first_submitted>
  <study_first_submitted_qc>April 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>April 15, 2021</last_update_submitted>
  <last_update_submitted_qc>April 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-small-cell lung cancer, next-generation sequencing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

